Who we are:
We focus on designing and making precision urine collection devices that fix collection processes, for which there are no protocols. Our work reduces the burden of repeat patient visits to GPs and outpatient clinics. We also reduce burden on labs of repeat tests and false-positives, allowing microbiology teams to focus on first-time tests – and adding value to managed service contracts.
What we do
Our flagship, precision FemTech urine collection device is evidence-based Peezy Midstream, as close to a collection protocol it’s possible to achieve for women’s health. The device reduces retests, false-positives and unnecessary prescribing. It transforms outcomes for healthcare providers and the 14.2m women required to collect midstream urine for UTI and prenatal screening as well as delivering huge direct and efficiency cost savings.
New devices in the pipeline are Peezy First Stream for STI and early stage cancer detection and Peezy Twin Stream for sports, evidential forensic and employer dope testing.
Why healthcare providers need us
Precision, precision, precision! Our work pinpoints the right urine sample for specific areas of medicine, revolutionising point-of-care urine collection and encouraging prevention of worsening and chronic conditions. Dramatic reduction of repeat processes create significant cost savings for NHS and private providers – over £300m in women’s health alone.
What have we achieved?
- Clinical evidence showing as low as 0% specimen contamination in GP Primary Care setting and 2.5% in antenatal clinics (national average between 20% and 30%)
- Sales in the UK and USA (250,000 units) until Covid suspended point of care testing
- Now relaunching in the UK with Pennine Healthcare
- Discussing home and remote testing opportunities with partners
What do we need?
- Sales and distribution partners for established and remote urine testing
- Investment
To find out more, discuss a sales or supply partnership or investment please write to giovanna.forte@forte-medical.com
